166 related articles for article (PubMed ID: 36097320)
41. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
[TBL] [Abstract][Full Text] [Related]
42. Impact of genetic polymorphisms on tacrolimus trough blood concentration in Chinese liver transplant recipients.
Maseko N; Yang S; Li C; Zhang S; Wang R; Zhang Y; Li C; Zhang C; Li L
Pharmacogenomics; 2023 Mar; 24(4):207-217. PubMed ID: 36927114
[No Abstract] [Full Text] [Related]
43. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
44. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
45. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
46. Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study.
Zhang Y; Zhang X; Zou Y; Sun Y; Li X
Xenobiotica; 2021 Dec; 51(12):1408-1415. PubMed ID: 34983304
[TBL] [Abstract][Full Text] [Related]
47. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE
Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583
[TBL] [Abstract][Full Text] [Related]
49. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.
Kassir N; Labbé L; Delaloye JR; Mouksassi MS; Lapeyraque AL; Alvarez F; Lallier M; Beaunoyer M; Théorêt Y; Litalien C
Br J Clin Pharmacol; 2014 Jun; 77(6):1051-63. PubMed ID: 24977292
[TBL] [Abstract][Full Text] [Related]
51. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients.
Willis C; Staatz CE; Tett SE
Ther Drug Monit; 2003 Apr; 25(2):158-66. PubMed ID: 12657909
[TBL] [Abstract][Full Text] [Related]
52. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.
Størset E; Holford N; Hennig S; Bergmann TK; Bergan S; Bremer S; Åsberg A; Midtvedt K; Staatz CE
Br J Clin Pharmacol; 2014 Sep; 78(3):509-23. PubMed ID: 25279405
[TBL] [Abstract][Full Text] [Related]
53. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
[TBL] [Abstract][Full Text] [Related]
54. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
[TBL] [Abstract][Full Text] [Related]
55. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
56. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
57. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
58. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
59. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.
Wang Z; Wu S; Chen D; Guo F; Zhong L; Fan J; Peng Z
Eur J Clin Pharmacol; 2014 Aug; 70(8):925-31. PubMed ID: 24820765
[TBL] [Abstract][Full Text] [Related]
60. Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.
Guy-Viterbo V; Baudet H; Elens L; Haufroid V; Lacaille F; Girard M; Debray D; Chardot C; Reding R; Wallemacq P; Musuamba F
Pharmacogenomics; 2014 Jun; 15(9):1207-21. PubMed ID: 25141896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
